Managing Director, Houston
Thomas has been working with entrepreneurs and allocating capital to promising companies for over a decade. Having founded multiple start-ups and working with management of many exciting young companies, Thomas is no stranger to the issues that early stage companies face. Prior to Allegory, Thomas was a partner of the DeSouza Perez Group at Robert W. Baird & Co. He joined Baird after his time at Morgan Stanley as a Portfolio Manager. Thomas is a Board Director of SemanticMD and an Independent Director of Scivanta Medical Corporation. Thomas attended both Portland State University with major coursework in Finance and Political Science as well as A.B. Freeman School of Business at Tulane University. He is a member in the Keiretsu forum where he is a member of the life sciences sub-committee. Thomas also serves as Director for The Residents' Foundation | Willamette View.
Managing Director, Portland
Kate has made a career of scrutinizing new advances in the life sciences and in guiding worthy enterprises in maximizing their potential, building value, and achieving recognition. She has served in executive roles in both private and publicly-traded life science companies and was previously a NASD-licensed sell-side equity research analyst covering the small cap biotechnology/life sciences sector. Kate graduated from Swarthmore College with a B.A., earned her Ph.D. in Pharmacology from Duke University, and she was the recipient of the first annual Harold M. Weintraub National Graduate Student of the Year Award.
David LaVance, J.D.
Venture Partner, Raleigh-Durham
Mr. LaVance is the Chairman of the Board of Hologic, Inc., a medical device and diagnostics company headquartered in Boston (HOLX). He is also the Chairman and CEO of Integrated Environmental Technologies, Ltd. (IEVM), a public company specializing in providing disinfectants and biocides to industry, and CEO of Scivanta Medical Corporation (SCVM), a publicly-traded medical device company focused on development of the Scivanta Cardiac Monitoring System. He is a co-founder of Century Capital Associates LLC. Mr. LaVance specializes in developing life science and other emerging technology companies as well as in advising companies about mergers, acquisitions, divestitures and strategic alliances. Mr. LaVance has extensive experience in strategic planning for biotechnology and medical device companies, technology licensing and international distribution.
Prior to co-founding Century Capital Associates, Mr. LaVance was a Managing Director of KPMG Health Ventures (1995-1997), a healthcare consulting group providing M&A, licensing and strategic advisory services. Before joining KPMG Health Ventures, Mr. LaVance was a founder of Physicians Data Corporation, a startup health informatics company (1994) and the President of Nuclear Care, Inc., a nuclear imaging clinical services provider (1992–1995). For both companies, he raised venture capital and recruited management.
He was the President of Dornier Medical Systems (Japan), Inc., a subsidiary of DaimlerBenz AG, and held a series of operating positions with Dornier in the United States (1987-1992). Dornier was the inventor of and world market leader in lithotripter technologies. Before joining Dornier, Mr. LaVance was Associate Counsel at Healthdyne, Inc. (1985-1986) where he led licensing, OEM and acquisition transaction efforts; and he was engaged in the private practice of law in Atlanta, Georgia (1979-1985).
During his career, Mr. LaVance has raised venture capital for several startup businesses and has led the acquisition or sale of numerous medical or high-tech companies. Mr. LaVance holds a B.A., cum laude, from Furman University (1976) and a J.D. from the Washington College of Law of the American University (1979).
Nancy Chang, Ph.D.
Venture Partner, Houston
Dr. Chang currently serves as the CEO/President of Apex Enterprises, Inc., an investment management company focused on investments in healthcare, education and socially responsible ventures. In addition to investing, Apex also participates in active operations of companies including STEAMtrax, LLC., where Dr. Chang is a member of the Board of Managers. From 2007 to 2012, she was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors L.L.C., one of the largest healthcare focused investment management firms in the world. Prior to that Dr. Nancy was the Co-Founder, President, Chief Executive Officer and Chairman of Tanox (1986-2006). Tanox focused its effort on the development of therapeutics to address major unmet medical needs in the areas of asthma, allergy, inflammation, aged macular degeneration and other diseases affecting the human immune system. In 2000, the company raised $250M and went public on NASDAQ making it the second largest Biotech IPO in the biotech industry. Tanox’s first product, Xolair, launched in 2003 and was a breakthrough drug that has changed the lives of many asthma suffers in the world. In 2007 Tanox was sold to Genetech for $919M. From 1980-1986 Dr. Chang held several leadership positions at Centocor, now a division of Johnson and Johnson. During 1986-1992, Dr. Chang also served as an Associate Professor at Baylor College of Medicine. Dr. Chang’s pharmaceutical development experience stemmed from her tenure at the Roche Institute of Molecular Biology from 1979-1980. Dr. Chang graduated from National Tsing Hua University in Taiwan and received her Ph. D. from Harvard University, the Division of Medical Sciences at Harvard Medical School in 1979.
In her over 30 year tenure in the biotechnology industry, she has developed and commercialized a number of highly successful diagnostic and therapeutic products. Even today, there are breakthrough drugs are coming to the market due to Dr. Chang’s work. Dr. Chang has served on the boards of a number of companies, including Charles River Laboratory International, Inc., Eddingpharm (Cayman) Inc., Crown Bioscience Inc., Applied Optoelectronics Inc., SciClone Pharmaceuticals Inc. and STEAMtrax, LLC. and many other private companies. In addition, Dr. Chang was a member of the board of directors at BIO (the Biotech Industry Organization in the U.S.) and BioHouston (the biotech industry organization in Houston, Texas) and recently Dr. Chang was elected to be on the board of Asia Society in Texas. Dr. Chang was also a Director at the Federal Reserve Bank in Dallas, Houston Branch from 2005 to 2009 and a Director for Project Hope.
Separately, Dr. Chang has received numerous awards including Junior Achievement’s Hall of Achievement (2014), Greater Houston Women’s Hall of Fame (2013), The Biotechnology Heritage Award – Co-sponsored by the Biotechnology Industry Organization and Chemical Heritage Foundation (2013), Chemical Heritage Foundation’s Woman in Chemistry (2012), Woman in Science Award in Houston (2012), American Biographical Institute’s Woman of the Year in Medicine & Healthcare (2010), BayHelix Lifetime Achievement Award (2010), Houston Technology Center’s Lifetime Achievement Award in Life Sciences (2009), Texas A&M University Center for New Ventures & Entrepreneurship’s Conn Family Entrepreneurial Leadership Award (2009), 150 Most Influential Business Leaders in Houston (2009), Forbes 25 Notable Chinese Americans (2008), Society of Chinese Bioscientists in America (SCBA) Life Time Pioneering Achievement in Biotech (2006), BioHouston Life Science Award – Tanox (2005), Harvard University Crimson Award for Leadership and Community Service (2005), MedAd News Magazine’s Most respected Woman in Biotechnology (2005), Global Federation of Chinese Business Women in Southern USA’s Global Business Achievement Hall of Fame Governor’s Award (2005), and many others.
Venture Partner, Portland
Jonathan has a strong record of successful business creation—launching more than 17 new businesses during his career. Prior to founding NorthShore Bio, a disruptive genome sequencing platform, Jonathan held both GM and group level Investment Manager positions with Intel Corporation’s New Business Initiatives Group (NBI)—an internal business incubator. Formerly, Jonathan was a founding member of Mercedes Benz Technology (GmbH), and as Head of Projects he started Mercedes Benz Technology Ventures and grew them from zero revenue to $50M in three years with IRRs of 20-50%. Prior to that, Jonathan was an early founder and group controller for Mercedes Benz International, Inc. Jonathan earned a BBA with honors, and holds certificates in management and finance.
John Holcomb, M.D.
Venture Partner, Houston
John Bradley Holcomb received his B.S. in Biology cum laude with honors from Centenary College in 1981and his M.D. from the University of Arkansas Medical School in 1985. Dr. Holcomb entered the U.S. Army in 1985, where he completed his general surgery internship in 1986 at the William Beaumont Army Medical Center. He served as Commander and General Medical Officer of the U.S. Army Health Clinic in Sinop, Turkey, followed by completion of his general surgery residency at the William Beaumont Army Medical Center in 1991. From 1991 to 1994, MAJ Holcomb served as Staff General Surgeon at the Womack Army Medical Center in Ft. Bragg, North Carolina, and started deploying with the US Special Operations Command (1991-2000). From 1994 to 1997, he was a General Surgery Attending at the William Beaumont Army Medical Center, where he established a productive surgical research program. In 1997, LTC Holcomb became the Chief of the Military Trauma Research Branch of the U.S. Army Institute of Surgical Research and Surgical Faculty at the Brooke Army Medical Center, where he established a new Hemostasis research program, spearheading the development of a well funded 5-year research plan.
In 1999, LTC Holcomb joined the surgical faculty of the Baylor College of Medicine and the Ben Taub General Hospital in the Texas Medical Center, Houston, Texas, and became the Director of the Joint Trauma Training Center. In 2001, he joined the University of Texas at Houston as a Surgical Critical Care Fellow and served as the Trauma Advisor to USSOCOM. From 2002 to 2008, COL Holcomb served as both Commander of the U.S. Army Institute of Surgical Research and Trauma Consultant for the Army Surgeon General, where he led the only Surgical Research Laboratory in the Department of Defense. He deployed in support of the war on terrorism 6 times and was intimately involved in establishing the Joint Trauma System. He was awarded the AAST Honorary Medal for Combat Surgical Care in 2004, the Department of the Army Research and Development Achievement Award for Leadership Excellence in 2005, and is a three time recipient of the Army’s Greatest Invention award (2004, 05, and 2007). His military awards include the Combat Medical Badge, Bronze Star, Legion of Merit, the Defense Meritorious Service Medal and the USSOCOM award, among many others. COL Holcomb retired from active duty on 23 July 2008. In 2008, he received the Lifetime Achievement Award in Trauma Resuscitation Science from the American Heart Association, the United States Special Operations Command Medal, and the Service award from the American College of Surgery, Committee on Trauma for outstanding scientific contributions to the surgery of trauma and dedication to the care of wounded warriors. He has served on the Tactical Combat Casualty Care Committee for the last decade, guiding the training and equipment needs for the DoD and many western countries.
In 2008, Dr. Holcomb joined the University of Texas Health Science Center at Houston as a Professor of Surgery and Head of the Division of Acute Care Surgery. He was named the Director of the newly established Center for Translational Injury Research, a university-wide center focused on translating preclinical research to the clinical arena. In 2009, he was named the University of Texas Chancellor’s Health Fellow for Trauma and Injury and Vice Chair of Surgery. Dr. Holcomb is actively involved in clinical medicine and resident and student education. His research interests include trauma, hemostasis, coagulopathy and trauma informatics. He has an established basic science laboratory in the area of vascular biology of trauma and is the PI of a NIGMS T-32 training grant. He reviews papers for more than 25 journals, has published over 400 peer reviewed articles and serves on multiple committees and editorial boards.